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Colorectal cancer is defined clinically as invasion of dysplastic cells into the submucosa.  
Lesions with submucosal invasion but without invasion into the muscularis propria are generally 
called malignant polyps. 
 A stepwise approach produces optimal management of malignant polyps (including 
polypoid and flat/depressed lesions). The first step is to avoid endoscopic resection of lesions 
with endoscopic features that predict deep submucosal invasion.  Lesions without such features 
are candidates for endoscopic resection.  The second step is to assess candidates for 
endoscopic resection for features that predict an increased risk of superficial submucosal 
invasion.  Such lesions should be considered for en bloc endoscopic excision if feasible.  The 
third step is giving patients with endoscopically resected malignant polyps good advice 
regarding whether to undergo adjuvant therapy, usually surgery. 
 We review the endoscopic and histologic criteria that guide clinicians through these 
steps. 
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Overview of the problem 
 A malignant colorectal polyp (“malignant polyp” is used generically here and includes 
polypoid and flat/depressed lesions) can be generally defined as a colorectal lesion with 
extension of dysplastic elements into the submucosa but not the muscularis propria 
1
.  In the 
TMN classification such lesions are pT1 
2
.  The general clinical problem posed when an 
endoscopically resected polyp is reported by a pathologist as malignant is whether to proceed 
with surgery to resect potential residual cancer in the bowel wall at the site of endoscopic 
resection, or the lymph nodes outside the bowel wall and near the resection site.  However, as 
described below, optimal endoscopic management involves recognition of endoscopic features 
of “deep submucosal invasion” which, when present in flat, depressed or sessile lesions, 
indicates the need to proceed directly to surgical resection without exposing the patient to the 
risk of endoscopic resection.  Furthermore, optimal management includes recognizing lesions 
that are at higher risk of “superficial submucosal invasion”, because en bloc resection 
techniques (if available and feasible) can allow some patients in this group to avoid surgical 
resection that would be more likely recommended in the case of piecemeal resection. 
  
 Decisions regarding management of malignant polyps that are already endoscopically 
resected can involve input from the endoscopist, one or more pathologists, a general or 
colorectal surgeon, an oncologist, and should generally involve the patient and/or her family.  
In some cases of malignant rectal lesions a radiation oncologist may be involved.  Involvement 
of multiple specialists will lead to better informed and improved decisions.  However, 
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endoscopists should have sufficient understanding of malignant polyps to lead the decision 
making process,  and either be the primary professional providing advice to the patient, or be 
able to contradict unsound advice if another specialist is coordinating care and decision making. 
 In most centers pathologists do not generally make clinical decisions.  However, 
pathologists play a critical role in the management of resected malignant colorectal polyps.  An 
endoscopist must know what information should be expected from the pathologist, and insist 
that the pathologic description be complete 
1
.   Anecdotally, there are many instances where 
pathologists provide incomplete information, or use terminology that mislead clinicians toward 
inappropriate decisions and advice to patients 
3
. 
 
EMR and ESD 
 Optimal management of malignant polyps involves translating pathology reports of 
malignant polyps into clinical decisions.  Endoscopists must also predict the presence of cancer 
is deeply invasive and thus should not be resected endoscopically but rather referred directly 
for surgical resection.   Endosocopists should also recognize lesions that have a higher risk of 
superficial submucosal invasion, as these lesions require a specialized approach to endoscopic 
resection and specialized handling of the tissue specimen by both the endoscopist and the 
pathologist.  Accurate identification and proper removal of superficially invasive malignant 
polyps is considered curative (2).  In contrast surgical resection may be necessary after 
piecemeal endoscopic resection and standard handling of resected specimens of a malignant 
polyp with superficial invasion 
3
.  The matter of how to resect and handle a lesion that is 
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suspected to contain superficially invasive cancer leads to an inevitable discussion of the pros 
and cons of endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) 
4,5
.  The disadvantage of EMR is that in larger flat or sessile lesions it will inevitably be 
performed piecemeal.  ESD however is in its very essence an attempt to resect lesions en bloc.  
Currently in the United States this remains a very challenging situation 
4
.  Expertise to perform 
ESD is not widely available, and ESD takes much longer to perform than EMR, is associated with 
a higher risk of perforation, need for hospitalization, and is without a reimbursement code. 
Some ESD experts in the U.S. are willing to perform rectal ESD but unwilling to perform colonic 
ESD, since colonic ESD has a relatively higher risk of complications.  A benefit of rectal ESD is 
that the alternative surgical procedures in the case of malignant rectal polyps are associated 
with greater morbidity than surgical colonic resections.  However, features that predict an 
increased risk of superficial submucosal invasion in a colorectal polyp, and therefore a 
candidate lesion for ESD, are as common in the colon as in the rectum.  Given the current 
limited expertise in ESD in the United States, and the other disadvantages of ESD mentioned 
above, the duty to refer a lesion with an increased (but still low) risk of superficial submucosal 
invasion must be balanced with the very limited availability and feasibility of ESD in the U.S 
4
. 
 
Definition of terms 
 
 Colorectal cancer is defined by invasion of neoplastic cells through the muscularis 
mucosa into the submucosa.  Without submucosal invasion, the term “cancer” should be 
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avoided.  The lamina propria is the histologic area of the mucosa between the epithelium and 
the muscularis mucosa.  Although some pathologists consider “cancer” in the lamina propria to 
be “invasive,” dysplastic changes in the lamina propria alone does not meet the clinically 
accepted definition of colorectal cancer 
2
.   A patient management problem arises when terms 
such as “intramucosal adenocarcinoma” are used to describe changes in the lamina propria of 
the mucosa, because any use of the word “adenocarcinoma” can be easily misinterpreted by 
clinicians and patients as equivalent to cancer, and thereby lead to incorrect decisions 
3
.  Based 
on our experience and discussion with Japanese experts, it is more common in the U.S. than in 
Japan for clinicians to incorrectly believe that colorectal neoplasia confined to the lamina 
propria and described as “ intramucosal adenocarcinoma” has the potential for distant 
metastasis.  Therefore many experts in the U.S. and other western countries recommend that 
such lesions be termed “high grade dysplasia.” Regardless of how they are described by a 
pathologist, such lesions must be understood by clinicians to have negligible risk of lymphatic or 
distant spread and are thus considered “benign”.  That is, all lesions with high grade dysplasia 
that are completely resected endoscopically have been cured, and do not require salvage 
surgical treatment. 
 Unless it has been specifically stated in the pathology report, the endoscopist should 
contact the pathologist to make sure that any use of the term “adenocarcinoma” in a colon 
polyp represents submucosal invasion. 
 “Deep submucosal invasion” refers to submucosal invasion depth greater 1000 microns 
(equal to 1 mm) and is emerging as an important determinant of prognosis in malignant sessile 
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and flat lesions. Since deep submucosal invasion predicts a higher risk of residual cancer and 
angiolymphatic spread and is generally an indication for surgical resection 
6
.  “Superficial 
submucosal invasion” refers to submucosal invasion depth less than 1000 microns, and is 
associated with a much lower risk of residual cancer in bowel wall angiolymphatic spread.  
These terms are described further below.  However, as already suggested, accurate 
measurement of depth of invasion requires en bloc endoscopic resection, special handling of 
the resected specimen, and a trained pathologist. 
 
Key clinical decision points 
 
 A skilled colonoscopist finds lesions (has a high adenoma detection rate and high 
detection rate of serrated class lesions), and resects them effectively 
7
.  Between detection and 
resection is the critical step of lesion assessment 
8
.  Every lesion should be assessed according 
to its size and Paris classification (Figure 1).  The surface is also assessed for features that 
predict deep submucosally invasive cancer (NICE III features – Table 1 or Kudo class V/Vn -
Figure 2).  Further, adenomatous lateral spreading tumors lesions are classified as granular or 
nongranular (Figure 3a-f).  These data are used to guide a sequence of clinical decisions:  
 
Decision point 1: Does the lesion have endoscopic features of deep submucosal invasion?  
If the lesion has endoscopic features of deep submucosal invasion 
9,10
, then generally the 
approach should be to obtain cold biopsy specimens from the portion of the lesion that 
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demonstrates the features, and the patient should be referred for surgical resection. High 
quality photographs, ideally with white light and image enhancement [e.g. narrow band 
imaging (NBI) Olympus Corp. Center Valley, PA, blue light imaging (BLI) Fujifilm Corp, Tokyo, 
Japan, iScan; Pentax Corp, Montvale, NJ, or dye based chromoendoscopy) should always be 
taken prior to biopsy.  As noted above, deep submucosal invasion refers histologically to > 
1,000 microns (1mm) of invasion into the submucosa.  This depth of invasion (which requires 
measurement with an optical micrometer) for accuracy, is associated with a high risk of lymph 
node metastases 
6
.  This relationship between the depth of the submucosal tumor invasion and 
the risk of lymph node metastases was described by Katajima et al 
6
 and is widely accepted as 
indicating the need for surgical resection in Japan, although it is infrequently measured by 
pathologists in the United States.  Regardless, the association of certain endoscopic features 
with deep submucosal invasion can be utilized by endoscopists worldwide.  When present, the 
endoscopic features of deep submucosal invasion are generally ulceration of the lesion surface, 
and inspection of the ulcerated area demonstrates disruption of the normal vascular and pit 
pattern 
9,10
.  These vascular and pit features are embodied in Type III of the NICE classification 
(Table 1) 
10,11
 and Type V/Vn of the Kudo classification 
9
(Figure 2).  Surface ulceration and 
stiffness of the lesion and colon wall are also predictive of deep submucosal invasion,  These 
features (Figure  4a-f) must be understood to be specific for deep submucosal invasion, 
although they are not sensitive for invasion overall, and are very insensitive for superficial 
submucosal invasion 
12
.  Only in instances of a patient who is a very poor surgical candidate 
should a sessile or flat lesion with endoscopic features of deep submucosal invasion undergo 
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endoscopic resection.  Endoscopists should understand that regardless of the method of 
endoscopic resection, including ESD, the presence of deep submucosal invasion generally 
indicates the need of surgical resection.  Thus, patients with deep submucosal invasion do not 
benefit from endoscopic resection including ESD.   
The above comments do not necessary apply to a pedunculated lesion that has features 
of deep submucosal invasion.  In a pedunculated lesion a deeper level of submucosal invasion 
could still be correlated with overall favorable histologic features 
6,13-15
, and might not warrant 
subsequent endoscopic resection. Thus, en bloc endoscopic snare resection is acceptable in the 
case of pedunculated adenomas that have features in the polyp head consistent with deep 
submucosal invasion e.g. (ulceration, NICE III features, Kudo Vn pits, stiffness in the polyp head, 
unusual thickening of the stalk).  Large pedunculated polyps, regardless of whether there are 
features of deep submucosal invasion in the inspected polyp head, should be resected en bloc.  
That is, extensive efforts should be made to get the snare entirely over the polyp head and 
around the stalk only, so that the polyp head will not be resected piecemeal.  Moving the snare 
further down the stalk toward the bowel wall increases the chance that any cancer present will 
be adequately resected (see below).  To correctly assess any cancer that may be present, the 
pedunculated polyp should be bi-sected through the head and stalk of the polyp by the 
pathology department 
1
. 
Decision point 2: If the lesion lacks features of deep submucosal invasion, then generally 
it is a candidate for endoscopic resection, either locally if there is sufficient endoscopic 
expertise, or at a center with advanced endoscopic expertise.  However, when  there is no  
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endoscopic evidence of deep submucosal invasion, the endoscopist must now consider if the 
lesion has a relatively increased risk of superficial submucosal invasion, since a higher risk of 
superficial submucosal invasion may affect the endoscopic resection approach.  
  
Unfortunately, unlike the case for endoscopic features of deep submucosal invasion, 
there are no  endoscopic predictors of superficial submucosal invasion that have adequate 
sensitivity or specificity
12
.  The endoscopist can only identify predictors associated with a 
relatively increased risk of superficial invasion, while realizing most lesions with these features 
will have no submucosal invasion.   
From the perspective of endoscopic resection, these issues apply only to 
nonpedunculated polyps.  Pedunculated lesions lacking features of deep submucosal invasion 
but with substantial size should, like all pedunculated lesions, be resected en bloc, and in the 
case of large size some consideration should be given to moving the snare close to the bowel 
wall.  This positioning increases the length of stalk on the specimen, and increases the 
possibility of a clear resection margin (see below) in pedunculated malignant polyps. 
For lesions with a broad attachment to the colon wall (nonpedunculated), and lacking 
endoscopic features of deep submucosal invasion, an increased risk of superficial submucosal 
invasion is associated with nongranular morphology (particularly with depression or bulky 
sessile shape), with depression in granular lateral spreading tumors (G-LST), and with dominant 
nodules in G-LSTs 
12
.  The surface pattern is also helpful at predicting superficial submucosal 
invasion.  Recently, the JNET classification 
20
(20) expands on the NICE classification to divide the 
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NICE II lesions (conventional adenomas) into JNET Type II A and Type II B (Table 1), with Type II 
B having an increased risk of superficial submucosal invasion.  However, JNET is designed to be 
used with magnifying colonoscopes. In the U.S., some degree of optical magnification on 
colonoscopes is increasingly available, but expertise and experience in using magnification is 
still very limited.  Anecdotally, some Japanese experts believe the near focus (optical 
magnification) function on the Olympus (Olympus Corp, Center Valley, PA) is adequate to apply 
the JNET classification, but published evidence to support this suggestion is not yet available.   
The endoscopist must understand that the histologic assessment of the depth of 
submucosal invasion requires an en bloc endoscopic resection. That is, superficial submucosal 
invasion cannot reliably be identified after piecemeal endoscopic mucosal resection.  An 
exception may be when a dominant nodule in a G-LST is resected and submitted separately to 
the pathologist. Other than this exception piecemeal EMR followed by a pathology reading of 
any submucosal invasion will lead to a recommendation for surgery regardless of invasion 
depth. 
In addition to an en bloc resection, endoscopists should pin the resected specimen on 
cork board or similar material so it lays flat before adding it to the formalin container.  If the 
specimen is placed directly into formalin without pinning, the edges will curl, rendering the 
measurement of submucosal invasion depth inaccurate.  Assessment of the lateral margins may 
also be compromised.  
For lesions with features associated with an increased risk of superficial submucosal 
invasion and less than 2 cm in diameter, en bloc resection can be achieved by using EMR or ESD.  
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Lesions > 2 cm usually require ESD to achieve en bloc resection.  As already noted, most lesions 
with the endoscopic features noted above that suggest an increased risk of submucosal 
invasion will have no submucosal invasion, and a few will have deep submucosal invasion. The 
question arises of how many will have superficial submucosal invasion and therefore benefit 
from en bloc resection by avoiding subsequent surgical resection.  In selected Japanese and 
Korean studies  ESD studies in which candidate lesions for ESD were large flat or sessile lesions  
lacking endoscopic features of deep submucosal invasion, , the answer is about 10% 
21-24
(21-
24).  This means that in carefully selected patients with a high risk of superficial submucosal 
invasion, about 10 ESDs must be performed (number needed to treat or NNT equals 10) for 1 
patient to benefit from ESD, and the benefit will be avoiding a subsequent surgery.  In some 
western ESD series, the NNT for one patient to avoid surgery by ESD (because en bloc resection 
of superficial submucosal cancer was achieved) rather than EMR is 30 
25-27
(25-27).  As noted 
above, this potential benefit of reduced need for surgery must be weighed against the cost in 
extra time, risk of perforation, increased need for hospitalization, and lack of reimbursement of 
ESD compared to piecemeal EMR.  Given these considerations, and given that long-term 
outcomes of piecemeal EMR followed by surgery compared to ESD are comparable, piecemeal 
EMR of these lesions is within the standard of medical care in the United States.  Many 
clinicians believe the high cost and risks of surgical resection of benign polyps 
16-19
(16-19), a 
problem that persists in the United States 
28
, is quantitatively a much more important 
healthcare outcomes issue compared to the small number of patients who undergo surgery 
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after piecemeal EMR of malignant polyps with superficial submucosal invasion compared to 
following treatment with ESD.   
Many of the lesions under consideration are found unexpectedly at the time of a 
screening/surveillance or diagnostic colonoscopy.  In some practice environments clinicians 
may proceed directly to large EMR.  However, many  experts now consider large EMR and 
certainly ESD to be  inappropriate without specific consent and expertise. In these settings 
these lesions should be well-photographed and marked with the smallest volume of  tattoo 
necessary  for later endoscopic resection. It is very important to avoid maneuvers that make 
subsequent EMR or ESD more difficult. These include aggressive tissue sampling (any snare 
method or even extensive cold biopsy) or tattooing directly under or immediately adjacent to 
the lesion. Both of these cause submucosal fibrosis which make subsequent EMR/ESD more 
challenging and riskier.  If local expertise for EMR and/or ESD is not available, referral to a 
regional center with advanced therapeutic endoscopic expertise is needed.  These lesions 
should not be referred directly to surgery regardless of size or morphology, because endoscopic 
therapy is associated with much lower cost and risk compared to surgery for treatment of 
benign polyps 
16-19
(16-19). 
 
 
 
Decision point 3: The polyp has been resected, and the pathology report demonstrates 
cancer (submucosal invasion).  Should the patient undergo surgical resection?  The question 
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generally implies that the lesion was resected en bloc, as noted above.  In the case of a 
pedunculated polyp that has been resected piecemeal, or has not been correctly sectioned in 
the pathology department so that the both the polyp head and the stalk can be assessed, 
proper assessment of the malignant features of the polyp may not be possible, and surgical 
resection may be the best course.  In a case of a nonpedunculated polyp resected piecemeal, 
surgical therapy is generally the preferred course.  In the case of en bloc resection, the 
approach to deciding on the need for subsequent surgical resection will vary between 
pedunculated and nonpedunculated polyps (see below). 
 
Estimating the risk  of residual cancer in the bowel wall and lymph nodes after 
endoscopic resection of malignant pedunculated polyps 
 
 When submucosal invasion (adenocarcinoma of the colon or rectum is identified in an 
endoscopically resected polyp, the pathologist must comment on the presence or absent of 
specific features (Table 2) associated with an increased risk of residual cancer in the bowel wall 
or lymph nodes.  The presence of one or more of these features are generally referred to as the 
presence of “unfavorable histologic criteria”, and would warrant a decision to proceed with 
surgical resection, unless the risk of surgical resection is considered to outweigh the risk of 
residual cancer.  Poor differentiation 
29,30
, which is present in about 5-10% of all colorectal 
cancers, and lymphovascular invasion 
31
, present in perhaps in 30% of all colorectal cancers, are 
both considered unfavorable histologic criteria.  Unfortunately, both are also subject to 
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substantial interobserver variation between pathologists
32
. Tumor budding, which refers to 
separated small (1-3) groups of cancer cells at the lead edge of the cancer 
6,33
, is less well 
defined as a poor histologic criterion in pedunculated lesions, but is an unwelcomed feature in 
any malignant polyp.  A criterion that can be considered in every pedunculated polyp is the 
proximity of the tumor to the resection line.  Although the original study by Basil Morson 
suggested the need for “clear resection margin 
34
,” a margin of at least 1 mm is advisable 
35
, 
and a margin of at least 2 mm is preferred 
36,37
.  It should be evident that the distance of the 
tumor from the resection line and the depth of submucosal invasion are two distinct concepts.  
At least some evidence suggest that the depth of invasion can be greater than 1000 microns in 
pedunculated polyps, and an excellent prognosis is preserved if all other criteria are favorable 
6,13-15
.  Another approach to risk evaluation in malignant pedunculated polyps is the Haggett 
criteria, which essentially state that cancer which is confined to the polyp head (Haggett levels 
1,2, 3) is associated with a zero risk of residual cancer while the risk increases with a Haggett 
level 4 (cancer invading the polyp stalk)
38
. 
 
Estimating  the risk of residual cancer in the bowel wall and lymph nodes after endoscopic 
resection of nonpedunculated polyps 
 
 For nonpedunculated polyps, as noted above for pedunculated polyps, the presence of 
poor tumor differentiation, lymphovascular invasion, and tumor budding are each considered 
unfavorable histologic criteria.  By definition, cancer in a nonpedunculated polyp is considered 
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Haggett level 4, and cancer in a nonpedunculated polyp is generally considered to be higher risk 
for residual disease than cancer in a pedunculated polyp.  If resected en bloc and appropriately 
handled by the endoscopist and the pathologist, the depth of invasion can be utilized to 
separate malignant nonpedunculated polyps with otherwise favorable histologic criteria into 
low and high risk lesions.  One approach to measuring the depth of invasion is to divide the 
submucosal into 3 levels as described by Kikuchi et al 
39
.  Cancers confined to the superficial 
third (SM1) and lacking unfavorable histologic criteria (lymphovascular invasion, poor 
differentiation, tumor budding) have a low risk of lymph node metastases and metastatic 
disease, and could be treated conservatively.  Because endoscopic resection does not normally 
include the muscularis propria there is uncertainty as how to divide the submucosa into thirds.  
Thus the Katajima criterion of greater or less than 1,000 microns of invasion has become 
standard in Japan 
6
.  Again, this generally requires en bloc resection, proper handling of the 
specimen with the endoscopist and pathologist, and use of an optical micrometer by the 
pathologist.  This process is seldom carried out in the United States.   
 
Advising the patient after endoscopic resection of a malignant colorectal polyp 
 
 When a malignant polyp has been removed by endoscopy, it may be good practice in 
many instances to obtain a baseline abdominal pelvic and chest CT scan with IV contrast to 
document absence of metastases, and a baseline CEA level.  This should generally be performed 
at least 3-4 weeks after endoscopic resection to allowed the bowel wall to heal and any 
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inflammatory lymphadenopathy to resolve.  It is critical to understand that these tests have no 
role in identifying the presence of residual cancer after endoscopic resection of a malignant 
polyp, and are therefore of no value in assisting the clinician in advising the patient regarding 
the need for surgical resection.  Rather, they serve as a clinical baseline in case there is a need 
for subsequent evaluation of potentially recurrent disease at a later date.  Neither CT scanning, 
MRI, or endoscopic ultrasound (EUS - in the case of rectal lesions) have sufficient sensitivity to 
detect residual cancer in the bowel wall or lymph nodes after resection of a malignant polyp 
1
.   
The general process of advising the patient regarding the need for surgery is as follows.  
For colonic malignant polyps with favorable histologic criteria, the patient is advised that the 
risk of residual disease is very low but not zero.  A healthy patient, particularly if younger, might 
choose segmental colonic resection and lymph node extraction despite favorable histologic 
criteria.  At the other end of the spectrum, in the case of an elderly patient with multiple 
comorbidities and unfavorable histologic criteria, observation may be the best course of action. 
In poor surgical candidates it should be remembered that most patients with unfavorable 
histologic criteria who undergo surgery will still have a surgical resection that is negative for 
residual cancer.  Cases with borderline histologic criteria and intermediate surgical risk pose the 
greatest challenge.  A widely accepted approach is to discuss the best estimates possible of 
residual cancer risk and surgical mortality and morbidity with the patient, and encourage them 
to actively participate in the decision.  The estimate of surgical risk may be altered by the 
surgeon or by a formal risk assessment by another specialist such as a cardiologist or a formal 
pre-operative risk assessment clinic.  The mortality of a segmental colon resection in persons 
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under the age 50 is below 1%, and is about 3% in healthy 80 year olds 
1,16-19,40
.  Both age and 
comorbidities influence the estimate of risk and benefit of surgical resection. 
In some cases, where endoscopic resection is deemed to be adequate, it may be 
appropriate to institute intensive surveillance.  In some series, intensive surveillance of 
malignant polyps without initial surgical resection, by periodic colonoscopy and CT scanning, 
has identified a substantial rate of cancer recurrences that are still resectable for cure 
41
.  
When surgery is selected, repeat colonoscopy at 1 year, 3 years, and 5 years is 
warranted for identification of metachronous (and missed synchronous) adenomas and cancer 
42
. 
For malignant rectal lesions, additional considerations apply.  A baseline EUS should be 
performed and consideration can be given to surgical full thickness resection of the endoscopic 
resection site using a transanal approach.  In some centers, EMR or ESD of the ulcer at the 
resection site is considered to determine if residual neoplasia is present at the resection site.   
The availability of the endoscopic full thickness resection device for use in the colon 
43,44
, may 
increase the use of endoscopic full thickness resection as adjuvant therapy after standard 
endoscopic resection of malignant polyps in the colon.  The morbidity of rectal surgery is higher 
than colonic surgery, and includes the risk of sexual dysfunction and low anterior syndrome. 
Further, the risk of local recurrence at any stage is higher for rectal compared to colonic cancers 
45
.  These factors lead to increased reliance on careful scheduled follow up for early recurrence, 
and in some cases the use of adjuvant chemoradiation is appropriate, though some centers 
may require proven residual disease before applying adjuvant chemoradiation. 
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Conclusions 
Optimal management of malignant polyps begins with endoscopic identification of 
lesions with specific endoscopic predictors of deep submucosal invasion that should be 
biopsied but not endoscopically resected (unless they are pedunculated).   Rather, these lesions 
should be referred for surgical resection.  If features of deep submucosal invasion are absent, 
the endoscopist should identify features that are associated with a higher risk of superficial 
submucosal invasion.  These features include sessile non-granular lateral spreading lesions, 
depression in granular and non-granular lateral spreading lesions, and granular lesions with 
dominant nodules.  If feasible en bloc resection of these lesions may allow a patient whose 
lesion has superficial submucosal invasion to avoid surgery. 
Once a malignant polyp has been resected, the endoscopist should be certain that all 
appropriate information has been provided by the pathologist.  Other specialists may provide 
important perspectives including assessment of surgical risk.  The risk-benefit ratio of adjuvant 
surgical resection or other treatments should be carefully explained to the patient and her 
family members that she chooses to involve in the decision making process.  In the case of a 
pedunculated malignant polyp, factors that favor surgical resection include piecemeal resection 
of the polyp head, poor orientation of the polyp head on the histologic slide,  poor tumor 
differentiation, lymphovascular invasion, and proximity of the cancer to the resection line.   In 
the case of a nonpedunculated lesion, surgical resection is favored by piecemeal resection, as 
well as any findings of poor tumor differentiation, lymphovascular invasion, and tumor budding.  
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In a non-pedunculated lesion that is resected en bloc and properly assessed histologically, deep 
(>1000 micron) submucosal invasion favors surgical resection.  As the availability and feasibility 
of endoscopic en bloc resections increases, the importance of proper handling and histologic 
handling of en bloc tissue specimens will increase. 
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Table 1.  The NICE classification 
*International NBI Classification (NICE) 
 Type 1 Type 2 Type 3 
Color Same or lighter 
than background 
Browner relative to 
background (verify 
color arises from 
vessels) 
Brown to dark 
brown relative to 
background; 
sometimes patchy 
whiter areas 
Vessels None, or isolated 
lacy vessels may be 
present coursing 
across the lesion 
Thick brown vessels 
surrounding white 
structures** 
Has area(s) with 
markedly distorted 
or missing vessels 
Surface 
Pattern 
Dark spots 
surrounded by 
white 
Oval, tubular or 
branched white 
structures** 
surrounded by 
brown vessels 
Distortion or 
absence of pattern 
Most likely 
pathology 
Hyperplastic or 
sessile polyp 
(adenoma) 
Adenoma** Deep submucosal 
invasive cancer 
 
 
The Japan Narrow Band Imaging Expert Team (JNET)* 
 Type 2a Type 2b 
Vessel 
pattern 
Regular caliber 
Regular distribution 
(meshed/spiral horn) 
Variable caliber 
Irregular distribution 
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Surface 
Pattern 
Regular 
(Tubular branched, 
papillary) 
Irregular or obscure 
Most 
likely 
histology 
Low-grade dysplasia High-grade dysplasia 
Shallow submucosal invasive 
cancer 
 
 
*JNET (The Japan Narrow Band Imaging Expert Team) was developed for magnifying 
colonoscopes.  NICE (Narrow Band Imaging International Colorectal Endoscopic) was developed 
for high definition non-magnifying colonoscopes.  JNET expands on NICE by dividing NICE Type 
2 into Types 2a and 2b, associated with low-grade and high-grade dysplasia, respectively.   
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Table 2.  Unfavorable histologic features in malignant pedunculated and non-pedunculated 
colorectal lesions * 
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Pedunculated lesions 
 Margin between the tumor and cautery line < 2 mm (see text) 
 Invasion of the stalk 
 Poor differentiation 
 Lymphovascular invasion 
 Inadequate orientation of the histologic sections 
Non-pedunculated lesions 
 Piecemeal resection 
 Positive resection margins 
 Invasion depth > 1000 microns 
 Poor differentiation 
 Lymphovascular invasion 
 Tumor budding 
 Inadequate orientation of the histologic sections 
 
 
 
 
 
Figure legends 
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Figure 1 The Paris classification of shapes of superficial gastrointestinal neoplasia 
Figure 2 The Kudo classification for prediction of histology of colorectal lesions by pit structure 
analysis 
Figure 3. 3a –c . Granular lateral spreading tumors.  Note the bumpy surface. 3d-f Nongranular 
lateral spreading tumors  
Figure 4. 4a White light image a non-granular lateral spreading tumor with deep submucosally 
invasive cancer.  The blue circle highlights an area seen in close-up and in magnification in 
Figure 4b.  4b.  Close-up narrow band imaging (NBI) view of the region in the blue circle in 4a.  
The yellow arrow points to a region of intact vessels of the NICE Type 2 pattern.  The red arrow 
shows an amorphous vascular and surface pattern (NICE Type 3).  4c. White light photograph of 
a malignant lesion in the cecum.  The area within the blue line is seen in close-up and 
magnification in 4d.  4d  Close-up, magnified NBI image of the area within the blue line in 4c.  
The yellow arrow points to a region of NICE Type 2 (adenomatous) vascular pattern.  The red 
arrows point to areas of disrupted vascular and surface pattern (NICE Type 3) consistent with 
deep submucosal invasion of cancer.  4e  A broad granular lateral spreading tumor in the 
cecum.  The area within the black line is seen in close-up and magnification in 4f.  4f.  The 
yellow arrow points to an area of intact vessels with the NICE Type 2 (adenomatous) pattern.  
The area within the yellow line is  a region of amorphous vascular and surface pattern 
consistent with deep submucosally invasive cancer (NICE Type 3). 
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